• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


Mismatch-negativity (MMN) is regarded as one of the most highly translatable studies around. It has proven invaluable in the field for developing drugs for schizophrenia.

What is MMN?

Mismatch negativity (MMN) is a negative component of the event-related response in an EEG signal, elicited by any perceptible change in some repetitive aspect of an auditory stimulation.

What we do?

We've applied our expertise in EEG to develop rodent mismatch negativity (MMN). We can conduct strict clinical research studies under specified conditions and provide you with reliable, quality data.

Contact us today to discuss your project requirements and get things underway: Tel: +44 (0)20 7691 0984 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design